search
Back to results

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Primary Purpose

Type 1 Diabetes, Organ Transplantation, Immunosuppression

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
islet transplantation
Sponsored by
University Hospital, Lille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes focused on measuring diabetes type 1, kidney transplantation, islet, hypoglycemia

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 1 diabetes mellitus. Documentation of negative basal and stimulated C-peptide and diagnosis of diabetes for at least 5 years.
  • Recipient of renal transplant with good function (creatinine clearance >/=60 ml/min)
  • Stable immunosuppression consisting of any combination of sirolimus, tacrolimus for at least 6 months, without major complications
  • Ability to give informed consent.
  • Age greater than or equal to 18 years or less than or equal to 65 years
  • No evidence of liver disease (liver enzymes < twice the upper limit of normal)

Exclusion Criteria:

  • Age below 18 years and above 65 years
  • Significant cardiovascular disease, including non-correctable coronary artery disease and/or recent myocardial infarction(within last 12 months); extensive peripheral vascular disease not correctable by surgery, unstable angina
  • Untreated proliferative retinopathy.
  • Recent Cerebrovascular accident (within last 12 months)
  • Recent unresolved acute infection, or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or positive skin test for TB
  • Any history of malignancy, except squamous or basal skin cancer or in situ cancer of the cervix.
  • History of non-compliance, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin pump therapy.
  • Psychiatric illness that is untreated, or likely to interfere significantly with transplantation despite treatment.
  • Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures for the duration of immunosuppressive therapy
  • Fasting C-peptide > 0.2 ng/ml
  • Creatinine > 25mg/l
  • Alkaline phosphatase, total bilirubin, Alanine Aminotransferase (ALT)or Aspartate Aminotransferase (AST) > twice the upper limit of normal
  • Significant liver disease (elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST, liver masses including portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e., gallstones).

Sites / Locations

  • University Hospital of Lille

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

islet transplantation

Arm Description

Islet transplantation

Outcomes

Primary Outcome Measures

Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation
Percent of insulin-independent patients with a Glycosylated Hemoglobin (HbA1c) under 8% at one year after injection of approximately 10,000 islets equivalents / kg (IE/kg).

Secondary Outcome Measures

The number of adverse events
The number of adverse events related to the procedure and to the immunosuppression
Number of severe episodes of hypoglycemia
Number of severe episodes of hypoglycemia (requiring the use of third)
Evaluation of Diabetes complications
Evaluation of Diabetes complications: retinopathy, neuropathy, nephropathy
Lipid metabolism
Lipid metabolism assessed by measurement of total cholesterol and HDL cholesterol, triglycerides, ApoA1, apoB, apoE, free fatty acids and lipid.
Evaluation of kidney function
Evaluation of kidney function (creatinine, creatinine clearance,proteinurie)

Full Information

First Posted
May 11, 2010
Last Updated
January 8, 2018
Sponsor
University Hospital, Lille
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
search

1. Study Identification

Unique Protocol Identification Number
NCT01123187
Brief Title
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Official Title
Phase 2 Study of Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation With Steroid Free Immunosuppression
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
March 2003 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
April 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This single center phase 2 clinical trial, is designed for confirming the efficacy and safety of sequential islet allotransplantation with steroid free immunosuppression in patients with previous kidney transplantation.
Detailed Description
The beneficial effects of glycemic control on both survival and function of transplanted kidneys in patients with type 1 diabetes mellitus have been recognized. The purpose of this study is to reverse hyperglycemia and insulin dependency, by islet cell transplantation, in patients with type 1 diabetes mellitus who have a stable kidney allograft. The study primary efficacy endpoint is graft survival defined as insulin independence and HbA1c < 8% at 1 year post first transplant. Secondary outcomes are graft function and metabolic control The immunosuppression protocol for the kidney graft was converted to sirolimus+tacrolimus regimen 6 months before islet transplantation to exclude negative effects on kidney graft function.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes, Organ Transplantation, Immunosuppression
Keywords
diabetes type 1, kidney transplantation, islet, hypoglycemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Islet transplantation
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
islet transplantation
Arm Type
Experimental
Arm Description
Islet transplantation
Intervention Type
Procedure
Intervention Name(s)
islet transplantation
Other Intervention Name(s)
surgical catheterisation, percutaneous catheterisation
Intervention Description
Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
Primary Outcome Measure Information:
Title
Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation
Description
Percent of insulin-independent patients with a Glycosylated Hemoglobin (HbA1c) under 8% at one year after injection of approximately 10,000 islets equivalents / kg (IE/kg).
Time Frame
One year
Secondary Outcome Measure Information:
Title
The number of adverse events
Description
The number of adverse events related to the procedure and to the immunosuppression
Time Frame
1 year
Title
Number of severe episodes of hypoglycemia
Description
Number of severe episodes of hypoglycemia (requiring the use of third)
Time Frame
1 year
Title
Evaluation of Diabetes complications
Description
Evaluation of Diabetes complications: retinopathy, neuropathy, nephropathy
Time Frame
1 year
Title
Lipid metabolism
Description
Lipid metabolism assessed by measurement of total cholesterol and HDL cholesterol, triglycerides, ApoA1, apoB, apoE, free fatty acids and lipid.
Time Frame
1 year
Title
Evaluation of kidney function
Description
Evaluation of kidney function (creatinine, creatinine clearance,proteinurie)
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes mellitus. Documentation of negative basal and stimulated C-peptide and diagnosis of diabetes for at least 5 years. Recipient of renal transplant with good function (creatinine clearance >/=60 ml/min) Stable immunosuppression consisting of any combination of sirolimus, tacrolimus for at least 6 months, without major complications Ability to give informed consent. Age greater than or equal to 18 years or less than or equal to 65 years No evidence of liver disease (liver enzymes < twice the upper limit of normal) Exclusion Criteria: Age below 18 years and above 65 years Significant cardiovascular disease, including non-correctable coronary artery disease and/or recent myocardial infarction(within last 12 months); extensive peripheral vascular disease not correctable by surgery, unstable angina Untreated proliferative retinopathy. Recent Cerebrovascular accident (within last 12 months) Recent unresolved acute infection, or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or positive skin test for TB Any history of malignancy, except squamous or basal skin cancer or in situ cancer of the cervix. History of non-compliance, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin pump therapy. Psychiatric illness that is untreated, or likely to interfere significantly with transplantation despite treatment. Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures for the duration of immunosuppressive therapy Fasting C-peptide > 0.2 ng/ml Creatinine > 25mg/l Alkaline phosphatase, total bilirubin, Alanine Aminotransferase (ALT)or Aspartate Aminotransferase (AST) > twice the upper limit of normal Significant liver disease (elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST, liver masses including portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e., gallstones).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
François PATTOU, MD, PhD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marie-Christine VANTYGHEM, MD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christian NOEL, MD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julie KERR-CONTE, MD
Organizational Affiliation
Université de Lille 2
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Lille
City
Lille
State/Province
Nord
ZIP/Postal Code
59000
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31615852
Citation
Vantyghem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, Raverdy V, Delalleau N, Machuron F, Hubert T, Frimat M, Van Belle E, Hazzan M, Pigny P, Noel C, Caiazzo R, Kerr-Conte J, Pattou F; Members of the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. Diabetes Care. 2019 Nov;42(11):2042-2049. doi: 10.2337/dc19-0401. Erratum In: Diabetes Care. 2020 May;43(5):1164.
Results Reference
derived
PubMed Identifier
28941330
Citation
Benomar K, Chetboun M, Espiard S, Jannin A, Le Mapihan K, Gmyr V, Caiazzo R, Torres F, Raverdy V, Bonner C, D'Herbomez M, Pigny P, Noel C, Kerr-Conte J, Pattou F, Vantyghem MC. Purity of islet preparations and 5-year metabolic outcome of allogenic islet transplantation. Am J Transplant. 2018 Apr;18(4):945-951. doi: 10.1111/ajt.14514. Epub 2017 Nov 11.
Results Reference
derived
PubMed Identifier
25393157
Citation
Caiazzo R, Vantyghem MC, Raverdi V, Bonner C, Gmyr V, Defrance F, Leroy C, Sergent G, Hubert T, Ernst O, Noel C, Kerr-Conte J, Pattou F. Impact of Procedure-Related Complications on Long-term Islet Transplantation Outcome. Transplantation. 2015 May;99(5):979-84. doi: 10.1097/TP.0000000000000458.
Results Reference
derived
PubMed Identifier
22996144
Citation
Vantyghem MC, Raverdy V, Balavoine AS, Defrance F, Caiazzo R, Arnalsteen L, Gmyr V, Hazzan M, Noel C, Kerr-Conte J, Pattou F. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (beta-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (beta-score greater than 3). J Clin Endocrinol Metab. 2012 Nov;97(11):E2078-83. doi: 10.1210/jc.2012-2115. Epub 2012 Sep 20.
Results Reference
derived

Learn more about this trial

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

We'll reach out to this number within 24 hrs